Progestin-based contraceptive on the same day as medical abortion

Area of Science:

• Reproductive Health
• Pharmacology
• Clinical Medicine

Background:

• Medical abortion is a common method for early pregnancy termination.
• Progestin-based contraceptives are frequently initiated postpartum or at intervals.
• Concurrent administration of contraceptives with medical abortion requires safety and efficacy evaluation.

Purpose of the Study:

• To assess the success rate of medical abortion when progestin-based contraceptives are given on the same day as mifepristone.
• To evaluate the safety and efficacy of initiating etonogestrel implants or DMPA injections during medical abortion.

Main Methods:

• Retrospective chart review of 89 women aged 15-49 years undergoing medical abortion (≤63 days gestation).
• Participants received oral mifepristone (200mg) and buccal misoprostol (800μg), with same-day etonogestrel implant or DMPA injection.
• Primary outcome: medical abortion success rate; comparative data sourced from PubMed.

Main Results:

• Complete abortion was achieved in 87 out of 89 women (98% success rate; 95% CI: 95%-100%).
• The observed success rate is comparable to historical data for medical abortion without concurrent contraceptive administration (94.8%).
• No adverse events related to concurrent administration were noted in the reviewed charts.

Conclusions:

• Initiating progestin-based contraceptives (etonogestrel implant or DMPA injection) on the same day as mifepristone does not compromise medical abortion success rates.
• This combined approach is a viable option for women seeking both pregnancy termination and ongoing contraception.
• Further research could explore patient satisfaction and long-term outcomes of this integrated care model.